Measurable residual disease (MRD) has become a key biomarker in the field of multiple myeloma (MM), and the sensitivity of MRD testing has increased in recent years. MRD can indicate the depth of response to treatment as well as patient outcomes, leading to suggestions of using MRD status to guide the treatment of patients with myeloma.
In this podcast, you will hear from Meral Beksac, MD, Ankara University, Ankara, Turkey, Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, and Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, who discuss the exciting potential applications of MRD in multiple myeloma and share insights from recent clinical trials.
CAR-T therapy in AML: challenges and future outlooks
The current state of CAR-T therapy in lymphoma
Myeloma treatment updates from EHA 2022
Updates in classification and risk stratification in MDS
Myeloma 2022: day one highlights
Immune dysregulation and targeting in MDS
The future of CAR-T therapy in ALL
An insight into novel targets in myeloma and mechanisms of resistance to PIs and IMiDs
Key updates in the treatment and management of MPNs
Addressing unmet needs and future treatment approaches in AL amyloidosis
Myeloma treatment in the UK: updates from Muk Nine b: OPTIMUM & the importance of genomics
Updates in lymphoma and CLL treatment in the UK
The importance of early intervention and interception in myeloma
Impact of the COVID-19 pandemic on the EBMT & projects in the pipeline
CAR-T and lymphoma treatment in the UK
Harnessing the power of immunotherapy in myeloma and amyloidosis
The impact of AI and machine learning algorithms in MDS
MMRF-CoMMpass: the genomic basis of myeloma subtypes
Genomics in the age of immuno-oncology
Understanding multiple myeloma at the single-cell level
Create your
podcast in
minutes
It is Free
The Relaxback UK Show
Good Nurse Bad Nurse
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive